SG
BIOR

StoneX Group’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

StoneX Group’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60
Closed -$1.97K – 780
2022
Q4 		$1.97K Buy
+60
New +$4.38K ﹤0.01% 536

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

StoneX Group's BIOR Position: Q1 2023 in Review

StoneX Group sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q1 2023, closing a stake of 60 shares — an estimated $1.97K sold.

StoneX Group first reported a position in BIOR in Q4 2022 and held it in 1 quarter. The position peaked at $1.97K in Q4 2022. 30 funds tracked by Wall St. Rank hold BIOR as of Q1 2023.

  • StoneX Group reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 60 Biora Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.97K.
  • StoneX Group first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • StoneX Group's Biora Therapeutics, Inc. Common Stock position peaked at $1.97K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.